Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
The New England journal of medicine, cilt.383, ss.2345-2357, 2020 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 383
- Basım Tarihi: 2020
- Doi Numarası: 10.1056/nejmoa2022485
- Dergi Adı: The New England journal of medicine
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
- Sayfa Sayıları: ss.2345-2357
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır
Özet
BackgroundWe previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The results of the final analysis of overall survival have not yet been reported.